Pharmacological characterization of the new stable antiarrhythmic peptide analog Ac-D-Tyr-D-Pro-D-Hyp-Gly-D-Ala-Gly-NH2 (ZP123): In vivo and in vitro studies

Journal of Pharmacology and Experimental Therapeutics

Volumn 306, Issue 3, 2003, Pages 1191-1199

  Kjølbye, Anne Louise ^a   Knudsen, Carsten Boye ^a   Jepsen, Trine ^a   Due Larsen, Bjarne ^a   Petersen, Jørgen Søberg ^a  

^a Zealand Pharma AS   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIARRHYTHMIC AGENT; OUABAIN; PEPTIDE DERIVATIVE; ROTIGAPTIDE; UNCLASSIFIED DRUG;

ACTION POTENTIAL; ANIMAL EXPERIMENT; ANTIARRHYTHMIC ACTIVITY; ARTICLE; ATRIOVENTRICULAR BLOCK; CONTROLLED STUDY; DISPERSION; DOSE RESPONSE; DRUG CLEARANCE; DRUG EFFICACY; DRUG ELIMINATION; DRUG STABILITY; HEART PERFUSION; HYPOKALEMIA; ISCHEMIA; MALE; NONHUMAN; PRIORITY JOURNAL; RAT;

ACTION POTENTIALS; ANIMALS; ANTI-ARRHYTHMIA AGENTS; DRUG STABILITY; HEART; HEMODYNAMIC PROCESSES; HUMANS; MICE; OLIGOPEPTIDES; RABBITS; RATS; TIME FACTORS;

EID: 0042889320     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: 10.1124/jpet.103.052258     Document Type: Article

References (19)

1. Aonuma S, Kohama Y, Akai K, Komiyama Y, Nakajima S, Wakabayashi M, and Makino T (1980) Studies on heart. XIX. Isolation of an atrial peptide that improves the rhythmicity of cultured myocardial cell clusters. Chem Pharm Bull (Tokyo) 28:3332-3339.
2. Aonuma S, Kohama Y, Makino T, and Fujisawa Y (1982) Studies of heart. XXI. Amino acid sequence of antiarrhythmic peptide (AAP) isolated from atria. J Pharmacobiodyn 5:40-48.
3. Argentieri T, Cantor E, and Wiggins JR (1989) Antiarrhythmic peptide has no direct cardiac actions. Experientia 45:737-738.
4. Dhein S, Manicone N, Muller A, Gerwin R, Ziskoven U, Irankhahi A, Minke C, and Klaus W (1994) A new synthetic antiarrhythmic peptide reduces dispersion of epicardial activation recovery interval and diminishes alterations of epicardial activation patterns induced by regional ischemia. A mapping study. Naunyn-Schmiedeberg's Arch Pharmacol 350:174-184.
5. Dikshit M, Srivastava R, Kundu B, Mathur KB, and Kar K (1988) Antiarrhythmic and antithrombotic effect of antiarrhythmic peptide and its synthetic analogues. Indian J Exp Biol 26:874-876.
6. Echt DS, Liebson PR, Mitchell LB, Peters RW, Obias-Manno D, Barker AH, Arensberg D, Baker A, Friedman L, and Greene HL (1991) Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial. N Engl J Med 324:781-788.
7. Gabrielson J and Weiner D (2000) Parameter Estimation, in Pharmacokinetic and Pharmacodynamic Data Analysis: Concepts & Applications, pp 21-44, Swedish Pharmaceutical Society, Stockholm.
8. Hjalmarson A (1984) MIAMI study - the advantage of acute treatment with metoprolol in AMI (suspected and clear). Metoprolol in acute myocardial infarction. Cardiologia 29:145-156.
9. ISIS-1 (1986) Randomised trial of intravenous atenolol among 16 027 cases of suspected acute myocardial infarction: ISIS-1. First International Study of Infarct Survival Collaborative Group. Lancet 2:57-66.
10. Kjolbye AL, Holstein-Rathlou NH, and Petersen JS (2002) Anti-arrhythmic peptide N-3-(4-hydroxyphenyl)propionyl Pro-Hyp-Gly-Ala-Gly-OH reduces dispersion of action potential duration during ischemia/reperfusion in rabbit hearts. J Cardiovasc Pharmacol 40:770-779.
11. Kohama Y, Kuwahara S, Yamamoto K, Okabe M, Mimura T, Fukaya C, Watanabe M, and Yokoyama K (1988) Effect of N-3-(4-hydroxyphenyl)propionyl Pro-Pro-Gly-Ala-Gly on calcium-induced arrhythmias. Chem Pharm Bull (Tokyo) 36:4597-4599.
12. Kohama Y, Okimoto N, Mimura T, Fukaya C, Watanabe M, and Yokoyama K (1987) A new antiarrhythmic peptide, N-3-(4-hydroxyphenyl)propionyl Pro-Hyp-Gly-Ala-Gly. Chem Pharm Bull (Tokyo) 35:3928-3930.
13. Muller A, Gottwald M, Tudyka T, Linke W, Klaus W, and Dhein S (1997a) Increase in gap junction conductance by an antiarrhythmic peptide. Eur J Pharmacol 327:65-72.
14. Muller A, Schaefer T, Linke W, Tudyka T, Gottwald M, Klaus W, and Dhein S (1997b) Actions of the antiarrhythmic peptide AAP10 on intercellular coupling. Naunyn-Schmiedeberg's Arch Pharmacol 356:76-82.
15. Naccarelli GV, Wolbrette DL, Patel HM, and Luck JC (2000) Amiodarone: clinical trials. Curr Opin Cardiol 15:64-72.
16. Ronsberg MA, Saunders TK, Chan PS, and Cervoni P (1986) The antiarrhythmic effect of antiarrhythmic peptide (Gly-Pro-4Hyp-Gly-Ala-Gly) and its analog on chemically-induced arrhythmias in mice. Med Sci 14:350-351.
17. Rowland M and Tozer TN (1989) Small volume of distribution, in Clinical Pharmacokinetics, Concepts and Applications, pp 438-450, Lea & Febiger, Philadelphia.
18. Waldo AL, Camm AJ, deRuyter H, Friedman PL, MacNeil DJ, Pauls JF, Pitt B, Pratt CM, Schwartz PJ, and Veltri EP (1996) Effect of d-sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction. The SWORD Investigators. Survival with oral d-sotatol [published erratum appears in Lancet 1996 Aug 10;348(9024):416]. Lancet 348:7-12.
19. Xing D, Kjølbye AL, Nielsen MS, Petersen JS, Harlow KW, Holstein-Rathlou N-H, and Martins JB (2003) ZP123 increases gap junctional conductance and prevents reentrant ventricular tachycardia during myocardial ischemia in open chest dogs. J Cardiovasc Electrophysiol 14:510-520.